Browse LUM

Summary
SymbolLUM
Namelumican
Aliases SLRR2D; lumican proteoglycan; LDC; KSPG lumican; keratan sulfate proteoglycan lumican
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF13516 Leucine Rich repeat
PF13855 Leucine rich repeat
PF01462 Leucine rich repeat N-terminal domain
Function

-

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001819 positive regulation of cytokine production
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0006790 sulfur compound metabolic process
GO:0007601 visual perception
GO:0018146 keratan sulfate biosynthetic process
GO:0030198 extracellular matrix organization
GO:0030199 collagen fibril organization
GO:0030203 glycosaminoglycan metabolic process
GO:0032905 transforming growth factor beta1 production
GO:0032908 regulation of transforming growth factor beta1 production
GO:0032914 positive regulation of transforming growth factor beta1 production
GO:0042339 keratan sulfate metabolic process
GO:0042340 keratan sulfate catabolic process
GO:0043062 extracellular structure organization
GO:0044272 sulfur compound biosynthetic process
GO:0044273 sulfur compound catabolic process
GO:0050953 sensory perception of light stimulus
GO:0051216 cartilage development
GO:0061448 connective tissue development
GO:0071604 transforming growth factor beta production
GO:0071634 regulation of transforming growth factor beta production
GO:0071636 positive regulation of transforming growth factor beta production
GO:1901136 carbohydrate derivative catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1903510 mucopolysaccharide metabolic process
Molecular Function GO:0005201 extracellular matrix structural constituent
GO:0005518 collagen binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005581 collagen trimer
GO:0005583 fibrillar collagen trimer
GO:0005775 vacuolar lumen
GO:0005796 Golgi lumen
GO:0043202 lysosomal lumen
GO:0044420 extracellular matrix component
GO:0098643 banded collagen fibril
GO:0098644 complex of collagen trimers
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3656244: Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
R-HSA-3656225: Defective CHST6 causes MCDC1
R-HSA-3656243: Defective ST3GAL3 causes MCT12 and EIEE15
R-HSA-1643685: Disease
R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism
R-HSA-3781865: Diseases of glycosylation
R-HSA-3000178: ECM proteoglycans
R-HSA-1474244: Extracellular matrix organization
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-216083: Integrin cell surface interactions
R-HSA-2022854: Keratan sulfate biosynthesis
R-HSA-2022857: Keratan sulfate degradation
R-HSA-1638074: Keratan sulfate/keratin metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolLUM
Namelumican
Aliases SLRR2D; lumican proteoglycan; LDC; KSPG lumican; keratan sulfate proteoglycan lumican
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LUM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolLUM
Namelumican
Aliases SLRR2D; lumican proteoglycan; LDC; KSPG lumican; keratan sulfate proteoglycan lumican
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LUM in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLUM
Namelumican
Aliases SLRR2D; lumican proteoglycan; LDC; KSPG lumican; keratan sulfate proteoglycan lumican
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LUM in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.640.0136
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.6820.407
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8640.694
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0760.924
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9880.681
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0850.737
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1440.872
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1710.938
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0830.975
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4260.625
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 283.6280.361
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2220.332
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LUM in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLUM
Namelumican
Aliases SLRR2D; lumican proteoglycan; LDC; KSPG lumican; keratan sulfate proteoglycan lumican
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LUM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLUM
Namelumican
Aliases SLRR2D; lumican proteoglycan; LDC; KSPG lumican; keratan sulfate proteoglycan lumican
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LUM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LUM.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLUM
Namelumican
Aliases SLRR2D; lumican proteoglycan; LDC; KSPG lumican; keratan sulfate proteoglycan lumican
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LUM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLUM
Namelumican
Aliases SLRR2D; lumican proteoglycan; LDC; KSPG lumican; keratan sulfate proteoglycan lumican
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LUM expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLUM
Namelumican
Aliases SLRR2D; lumican proteoglycan; LDC; KSPG lumican; keratan sulfate proteoglycan lumican
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LUM and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLUM
Namelumican
Aliases SLRR2D; lumican proteoglycan; LDC; KSPG lumican; keratan sulfate proteoglycan lumican
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LUM collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting LUM.
ID Name Drug Type Targets #Targets
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141